Vir Biotechnology (VIR) Change in Account Payables (2018 - 2026)

Vir Biotechnology has disclosed Change in Account Payables across 9 years of filings, most recently posting -$4.2 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$4.2 million, down 198.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 169.66% YoY), and the FY2025 annual result was $5.0 million, up 605.77% from the prior year.
• Change in Account Payables came in at -$4.2 million for Q1 2026 at Vir Biotechnology, down from $3.0 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $8.9 million in Q2 2025 to a low of -$7.5 million in Q3 2023.
• The 5-year median for Change in Account Payables is -$934000.0 (2023), against an average of $77176.5.
• Peak annual rise in Change in Account Payables reached 406.22% in 2025, while the deepest fall reached 292.52% in 2025.
• Vir Biotechnology's Change in Account Payables stood at $2.8 million in 2022, then retreated by 6.18% to $2.6 million in 2023, then plunged by 173.7% to -$1.9 million in 2024, then surged by 252.63% to $3.0 million in 2025, then sank by 243.01% to -$4.2 million in 2026.
• The last three Change in Account Payables figures came in at -$4.2 million (Q1 2026), $3.0 million (Q4 2025), and -$5.4 million (Q3 2025), per Business Quant data.